Timing of interferon therapy and sources of infection in patients with acute hepatitis C

Hepatology Research

Volumn 34, Issue 1, 2006, Pages 35-40

  Ogata, Kei ^a   Ide, Tatsuya ^a   Kumashiro, Ryukichi ^a   Kumada, Hiromitsu ^b   Yotsuyanagi, Hiroshi ^c,n   Okita, Kiwamu ^d   Akahane, Yoshihiro ^e,o   Kaneko, Shuichi ^f   Tsubouchi, Hirohito ^g,p   Tanaka, Eiji ^h   Moriwaki, Hisataka ⁱ   Nishiguchi, Shuhei ^j,q   Kakumu, Shinichi ^k   Mizokami, Masashi ^l   Iino, Shiro ^m   Sata, Michio ^a  

^a KURUME UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^g UNIVERSITY OF MIYAZAKI   (Japan)

^h SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^m Kiyokawa Hospital   (Japan)

ⁿ UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^o Kofu Municipal Hospital   (Japan)

^p KAGOSHIMA UNIVERSITY   (Japan)

^q HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Acute hepatitis; Hepatitis C virus (HCV); Interferon; Medical procedure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; CONSENSUS INTERFERON; INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HEALTH SURVEY; HEPATITIS C; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SYMPTOM; VIROLOGY;

EID: 30744431602     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.08.012     Document Type: Article

References (38)

1. H.J. Alter L.B. Seeff Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome Semin Liver Dis 20 2000 17-35
2. T. Poynard P. Bedossa P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825-832
3. A. Alberti S. Boccato A. Vario L. Benvegnu Therapy of acute hepatitis C Hepatology 36 Suppl. 2002 195-200
4. E. Jaeckel M. Cornberg H. Wedemeyer et al. Treatment of acute hepatitis C with interferon alfa-2b N Engl J Med 345 2001 1452-1457
5. F. Komine T. Yamaguchi M. Moriyama et al. A case of sexually transmitted acute hepatitis C: Confirmation by analysis of viral genome Hepatol Res 14 1999 84-91
6. A. Kowala-Piaskowska M. Figlerowicz I. Mozer-Lisewska et al. Vertical transmission of hepatitis C virus infection Hepatol Res 30 2004 137-140
7. T. Saito H. Watanabe L. Shao et al. Transmission of hepatitis C virus quasi species between human adults Hepatol Res 30 2004 57-62
8. M. Omata O. Yokosuka S. Takano et al. Resolution of acute hepatitis C after therapy with natural beta interferon Lancet 338 1991 914-915
9. S.J. Hwang S.D. Lee C.Y. Chan R.H. Lu K.J. Lo A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C J Hepatol 21 1994 831-836
10. S. Takano Y. Satomura M. Omata Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study Gastroenterology 107 1994 805-811
11. P. Lampertico M. Rumi R. Romeo et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C Hepatology 19 1994 19-22
12. W. Vogel I. Graziadei F. Umlauft et al. High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C. A pilot study Dig Dis Sci 41 Suppl. 1996 81-85
13. C. Camma P. Almasio A. Craxi Interferon as treatment for acute hepatitis C. A meta-analysis Dig Dis Sci 41 1996 1248-1255
14. Japanese Red Cross non A, non B-hepatitis Research Group Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis Lancet 338 1991 1040-1041
15. S. Noguchi M. Sata H. Suzuki K. Ohba M. Mizokami K. Tanikawa GB virus C (GBV-C)/hepatitis G virus (HGV) infection among intravenous drug users in Japan Virus Res 49 1997 155-162
16. K. Kiyosawa T. Sodeyama E. Tanaka et al. Hepatitis C in hospital employees with needlestick injuries Ann Intern Med 115 1991 367-369
17. T. Tanaka K. Tsukiyama-Kohara K. Yamaguchi et al. Significance of specific antibody assay for genotyping of hepatitis C virus Hepatology 19 1994 1347-1353
18. A. Mele E. Spada L. Sagliocca et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy J Hepatol 35 2001 284-289
19. C. Vivas-Arceo S.A. Benavides J. De Jesus Trujillo et al. Hepatitis C virus: Prevalence and routes of infection among blood donors of West Mexico Hepatol Res 25 2003 115-123
20. M.J. Alter H.S. Margolis K. Krawczynski et al. ]The natural history of community-acquired hepatitis C in the United States N Engl J Med 327 1992 1899-1905
21. E. Tanaka K. Kiyosawa Natural history of acute hepatitis C J Gastroenterol Hepatol 15 Suppl. 2000 97-104
22. H. Hofer T. Watkins-Riedel O. Janata et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load Hepatology 37 2003 60-64
23. J.T. Gerlach H.M. Diepolder R. Zachoval et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80-88
24. H. Nomura S. Sou H. Tanimoto et al. Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial Hepatology 39 2004 1213-1219
25. + T cells with viral clearance in acute hepatitis C J Infect Dis 181 2000 1528-1536
26. H.M. Diepolder R. Zachoval R.M. Hoffmann et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection Lancet 346 1995 1006-1007
27. G. Missale R. Bertoni V. Lamonaca et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response J Clin Invest 98 1996 706-714
28. R. Thimme D. Oldach K.M. Chang C. Steiger S.C. Ray F.V. Chisari Determinants of viral clearance and persistence during acute hepatitis C virus infection J Exp Med 194 2001 1395-1406
29. R. Thimme J. Bukh H.C. Spangenburg et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease Proc Natl Acad Sci USA 99 2002 15661-15668
30. + T cells in acute and chronic hepatitis C Hepatology 37 2003 1189-1198
31. H. Wedemeyer X.S. He M. Nascimbeni et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection J Immunol 169 6 2002 3447-3458
32. M. Sata O. Hashimoto S. Noguchi et al. Transmission routes and clinical course in sporadic acute hepatitis C J Viral Hepat 4 1997 273-278
33. M. Sata T. Ide S. Noguchi et al. Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick J Hepatol 27 2 1997 425-426
34. A. Licata D.D. Bona F. Schepis L. Shahied A. Craxi C. Camma When and how to treat acute hepatitis C? J Hepatol 39 2003 1056-1062
35. E.J. Heathcote M.L. Schiffman W.G. Cooksley et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673-1680
36. S. Zeuzem S.V. Feinman J. Rasenack et al. Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666-1672
37. M.P. Manns J.G. McHutchison S.C. Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 2001 958-965
38. T. Santantonio M. Fasano E. Sinisi et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance J Hepatol 2005 42 329-333